BLU2864 is an orally active, highly selective, ATP-competitive PRKACA inhibitor (IC50=0.3 nM). BLU2864 shows anti-tumor activity. BLU2864 can be used in cancer and polycystic kidney disease research[1][2].
Molecular Weight:
452.43
Purity:
99.50
CAS Number:
[2810747-89-6]
Formula:
C24H19F3N4O2
Target:
PKA
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted